Literature DB >> 23443144

Predictive values for the severity of avascular necrosis from the initial evaluation in closed reduction of developmental dysplasia of the hip.

Mai Xu1, Shuguang Gao, Jinpeng Sun, Yang Yang, Yang Song, Rui Han, Guanghua Lei.   

Abstract

The severity of avascular necrosis (AVN) after closed reduction of developmental dysplasia of the hip determines the final clinical outcomes. Our study aimed to correlate the possible predictors with the severity of AVN. After follow-up of the patients on skeletal maturity, 37 patients (39 hips) were included. Age at reduction is important to predict the severity of AVN. Older patients are at a greater risk of suffering from more severe AVN. Other values such as the degree of initial dislocation or the impact of the femoral head ossific nucleus show no precognition to the severity of AVN.

Entities:  

Mesh:

Year:  2013        PMID: 23443144     DOI: 10.1097/BPB.0b013e32835f1f7a

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  3 in total

1.  Radiographic outcome of children older than twenty-four months with developmental dysplasia of the hip treated by closed reduction and spica cast immobilization in human position: a review of fifty-one hips.

Authors:  YiQiang Li; YueMing Guo; XianTao Shen; Hang Liu; HaiBo Mei; HongWen Xu; Federico Canavese
Journal:  Int Orthop       Date:  2019-04-12       Impact factor: 3.075

2.  Does Perfusion MRI After Closed Reduction of Developmental Dysplasia of the Hip Reduce the Incidence of Avascular Necrosis?

Authors:  Alex L Gornitzky; Andrew G Georgiadis; Mark A Seeley; B David Horn; Wudbhav N Sankar
Journal:  Clin Orthop Relat Res       Date:  2016-05       Impact factor: 4.176

Review 3.  Outcome Prognostic Factors in MRI during Spica Cast Therapy Treating Developmental Hip Dysplasia with Midterm Follow-Up.

Authors:  Katharina Susanne Gather; Ivan Mavrev; Simone Gantz; Thomas Dreher; Sébastien Hagmann; Nicholas Andreas Beckmann
Journal:  Children (Basel)       Date:  2022-07-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.